Kovalenko E.I.; Artamonova E.V.; Bolotina L.V.; Zhiliaeva L.A.; Ponomarenko D.M.; Karabina E.V.; Mukhametshina G.Z.; Khasanova A.I.; Ratner E.Y.; Safarova A.R.; Manikhas A.G.; Popova N.O.; Evstigneeva I.V.; Vladimirova L.Y.; Kramskaya L.V.; Karandeeva T.V.; Suslova I.R.; Romanchuk O.V.; Shikina V.E.; Povyshev A.Y.; Osipov M.A.; Cherniakova E.M.; Dergunov A.S.; Volkonskiy M.V.; Chernov I.S.; Shumskaya I.E.; Fael M.M.; Garifullina V.I.; Gudkova I.E.
(2021)
Introduction. The standard of 1st line treatment of HER2+ metastatic breast cancer (mBC) is double blockade with trastuzumab and pertuzumab + taxane, 2nd line – Trastuzumab-emtazine. There are no standards for further ...